Gokul Kannan
The CEO of C3 Therapeutics tells us how they're building a new class of antivirals, discusses a useful mental model for understanding biology, how to manage risk, and exciting emerging science
Gokul Kannan (C3 Therapeutics) The CEO of C3 Therapeutics tells us how they're building a new class of antivirals, discusses a useful mental model for understanding biology, how to manage risk, and exciting emerging science David Huang Jan 04, 2021 3 Share Welcome to the 7th issue of Master Plan , a series of conversations with hard tech founders solving really difficult problems. Gokul Kannan is the co-founder and CEO of C3 Therapeutics, a biotech company developing broad-spectrum antivirals. Gokul is one of the most passionate scientists I’ve ever met, and you can always learn something from
Explore this link on the map →related reading
- jsomers.net | I should have loved biologyjsomers.net
- Why is progress in biology so slow?sam-rodriques.com
- Gap Mapgap-map.org
- Models of Lifepress.asimov.com
- Levers for Biological Progress - by Niko McCartyasimov.press
- There aren't enough smart people in biology doing something boringowlposting.com
- Hub-and-Spoke Biotechs: BridgeBio - by Elliot Hershbergcenturyofbio.com
- Curious cases of financial engineering in biotechowlposting.com
- Paving the way for agents in biology \ Anthropicanthropic.com
- A billion years of evolution in a single afternoon — George Churchdwarkesh.com
- Tech vs Biotech - Celine Haliouacelinehh.com
- Kevin Esvelt and Jonas Sandbrink on Risks from Biological Research - Hear This Ideahearthisidea.com